For the quarter ending 2025-09-30, SABSW had $20,526,742 increase in cash & cash equivalents over the period.
| Cash Flow | 2025-09-30 |
|---|---|
| Net income (loss) | 30,134,426 |
| Depreciation and amortization | 2,253,170 |
| Amortization of finance right-of-use assets | 65,117 |
| Stock-based compensation expense | 2,040,913 |
| Net realized and unrealized gain on equity securities | 64,038 |
| Change in fair value of warrant liabilities | -66,007,621 |
| Accretion of discounts on short-term investments | 51,767 |
| Accrued interest receivable | 504,999 |
| Prepaid expenses and other current assets | -1,577,810 |
| Operating lease right-of-use assets and liabilities, net | -63,559 |
| Accounts payable | 1,158,266 |
| Accrued expense and other current liabilities | 1,336,380 |
| Net cash used in operating activities | -27,998,784 |
| Proceeds from the sale of equipment | 500 |
| Purchases of investment securities | 129,991,839 |
| Sales and maturities of investments | 9,991,364 |
| Net cash used in investing activities | -119,999,975 |
| Proceeds from the 2025 pipe, net of series b issuance costs | 168,729,827 |
| Principal payments of notes payable | 275,849 |
| Principal payments on finance leases | 105,888 |
| Tax payments for share settlement of restricted stock units | 6,953 |
| Net cash provided by (used in) financing activities | 168,341,137 |
| Effect of exchange rate changes on cash and cash equivalents | 184,364 |
| Net increase (decrease) in cash and cash equivalents | 20,526,742 |
| Cash and cash equivalents at beginning of period | 8,897,966 |
| Cash and cash equivalents at end of period | 29,424,708 |
SAB Biotherapeutics, Inc. (SABSW)
SAB Biotherapeutics, Inc. (SABSW)